Is Hims & Hers Stock Back on the Larger Uptrend as Peptide Push and Weight-Loss Demand Boost Sentiment?
Hims & Hers Health is staging a strong comeback as optimism around weight-loss drugs and regulatory changes lifts investor sentiment.
Quick overview
- Hims & Hers Health is experiencing a stock rebound, gaining up to 8% as investor sentiment improves due to optimism around weight-loss drugs and regulatory changes.
- The company's GLP-1 weight-loss strategy, utilizing FDA-approved treatments like Wegovy and Ozempic, is gaining traction with management projecting high prescription demand.
- Recent regulatory developments, including potential easing of peptide restrictions by the FDA, are creating new opportunities for Hims to expand its offerings.
- Despite short-term revenue pressures from a strategic pivot towards FDA-approved drugs, the company's long-term growth outlook remains positive.
Hims & Hers Health is staging a strong comeback as optimism around weight-loss drugs and regulatory changes lifts investor sentiment.
Stock Rebounds on Renewed Optimism
Hims & Hers Health shares climbed sharply, gaining as much as 8% on Monday and extending last week’s rally. The move follows months of decline and signals a potential shift in momentum as investors return to the stock.
The rebound is being driven by renewed enthusiasm for the company’s weight-loss strategy, combined with supportive regulatory developments. A key catalyst was the FDA’s announcement of a meeting to review peptide regulations, a move strongly supported by Robert F. Kennedy Jr..
GLP-1 Strategy Gains Traction
At the core of the rally is growing confidence in Hims’ GLP-1 weight-loss offering. The company is scaling its platform using FDA-approved treatments from Novo Nordisk, including Wegovy and Ozempic.
Management has indicated that prescriptions for Wegovy could exceed 100,000 per month, highlighting strong demand in a rapidly expanding market. The shift toward branded, regulated treatments also strengthens the company’s credibility compared to compounded alternatives.
Rebound Gains Strength
Hims & Hers Health stock has been under pressure since October, but sentiment has shifted in recent weeks. After an initial rebound in early March, the stock is gaining further traction, rising around 35% last week and pushing above the $30 level.
From a technical perspective, HIMS has broken above its 50-day moving average, signaling improving short- to medium-term momentum. However, it remains below the 200-day moving average near $38, suggesting that longer-term resistance still caps the upside.
HIMS Chart Daily – Overtaking the 100 SMA
Regulatory Shift Opens New Opportunities
Regulatory developments are adding further momentum. The FDA is considering easing restrictions on peptides, potentially removing several from its controlled list. This could create new opportunities for telehealth platforms like Hims to expand their offerings.
Robert F. Kennedy Jr. has been a vocal advocate for peptides, and his influence is seen as a contributing factor behind the renewed regulatory discussion. Hims has already positioned itself strategically, having acquired a peptide manufacturing facility in California to support future production.
Strategic Pivot and Near-Term Pressure
In March 2026, Hims announced a strategic shift in its weight-loss business, prioritizing FDA-approved drugs such as Wegovy while limiting compounded semaglutide to specific cases. This move aligns with increasing regulatory scrutiny but is expected to create a temporary revenue headwind of around $65 million due to delayed shipments.
Despite this short-term impact, the transition is viewed as a positive step toward long-term sustainability and compliance.
Growth and Sentiment Recovery
The rally also reflects improving sentiment following earlier concerns, including data security issues, as well as potential short-covering activity.
On the growth front, Hims continues to expand internationally, with strong revenue growth driven by acquisitions such as ZAVA and Livewell. This expansion highlights the company’s ambition to scale beyond the U.S. market.
Outlook
Hims & Hers’ recent rebound underscores a shift in investor focus toward long-term growth opportunities in digital health and weight-loss treatments. While regulatory clarity remains a key variable, the combination of strong demand, strategic positioning, and policy tailwinds suggests momentum could continue.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
- Read our latest reviews on: Avatrade, Exness, HFM and XM
Related Articles
Sidebar rates
Save